Revenue (Tables)

9 Months Ended

Sep. 30, 2022

Revenue from Contract with Customer [Abstract]

Summary of Revenues

The Company recorded the following revenues (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Product sales, net:
ORLADEYO	$	65,395	$	36,711	$	179,492	$	76,023
RAPIVAB	6,953		2,430		7,290		7,165
Peramivir	2,865		—		2,865		7,254
Total product sales, net	75,213		39,141		189,647		90,442
Royalty revenue	600		322		1,487		(447)
Milestone revenue	—		—		—		15,000
Collaborative and other research and development revenues:
U.S. Department of Health and Human Services	14		1,531		148		5,017
Total collaborative and other research and development revenues	14		1,531		148		5,017
Total revenues	$	75,827	$	40,994	$	191,282	$	110,012